CTRI/2022/08/044663招募中未知
A perspective case-controlled study 0f FOXP3 gene mutation in migraine patients
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1.Migraine with aura (MWA) and Migraine without aura (MWOA) patients
- •2.Patients above 18 years old
- •3.Patients affected by COVID-19
- •4.Patients who have all been vaccinated against COVID-19, either with both doses or a single dose
排除标准
- •1.Patients with additional comorbidity conditions were not allowed to participate.
- •2.Patients who have recently taken any immunosuppressants
- •3.Pregnant women were excluded
- •4.Patients with previous head injury
研究者
相似试验
已完成
3 期
Randomized Phase III Study of mFOLFOX7 or CAPOX plus Bevacizumab versus 5-Fluorouracil/Leucovorin or Capecitabine plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer (JCOG1018, RESPECT)Metastatic clorectal cancerJPRN-UMIN000008866Japan Clinical Oncology Group (JCOG)250
已完成
不适用
Relationship between perinatal FOXP3 positive T cells and histone deacetylaseJPRN-UMIN000036079Juntendo University Graduate School of Medicine20
已完成
3 期
Randomized phase III study of FOLFOX plus bevacizumab versus FOLFIRI plus bevacizumab for metastatic colorectal cancermetastatic colorectal cancerJPRN-UMIN000001396West Japan Oncology Group400
尚未招募
2 期
Evaluation of preferred chemotherapy regimen during esophageal cancer radiotherapyesophageal cancer.Malignant neoplasm of esophagusIRCT20240701062297N1Tehran University of Medical Sciences98
进行中（未招募）
1 期
FOLFOXIRI plus Panitumumab or FOLFOX plus Panitumumab in the treatment of metastatic colorectal cancer.Metastatic Colorectal CancerMedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2016-004394-40-ITFondazione GONO432